therapeutic action: fungal clearance

Naganishia albidus Causing Perioral Cutaneous Infection: A Rare Case Easily Misdiagnosed

mycolabadmin

A 37-year-old man developed an unusual fungal skin infection around his mouth caused by Naganishia albidus, a rare yeast. He was initially misdiagnosed with eczema and his condition worsened with wrong treatment. Advanced fungal testing techniques helped identify the correct organism, and after six weeks of antifungal medication (both oral and topical), his skin completely cleared. This case shows why doctors need to consider rare fungal infections when skin problems don’t respond to typical treatments.

Read More »

Severe Outbreak of Saprolegnia Spp. Infection in Spotted Snakehead (Channa punctata, Bloch 1793): Clinical Assessment, Histopathology, Haemato-Biochemical Indices and Insights Into Therapeutic Effects

mycolabadmin

A severe fungal infection called saprolegniasis was found in 85% of spotted snakehead fish from Bangladesh, causing cotton-like growths, fin damage, and mass mortality. Researchers tested four different treatments over 10 days, finding that combining warm water (30°C) with saltwater (2% NaCl) was most effective, resulting in 70% survival compared to only 23% in untreated fish. This natural, cost-effective treatment approach could help fish farmers reduce losses from fungal diseases without relying on toxic chemicals.

Read More »

Schizophyllum commune infection following chimeric antigen receptor T-cell therapy in a patient with lymphoma

mycolabadmin

A 71-year-old woman receiving CAR T-cell therapy for lymphoma developed a rare fungal lung infection caused by Schizophyllum commune six months after treatment. The infection presented similarly to other fungal diseases affecting the lungs and was diagnosed through bronchoscopy and fungal culture despite negative blood antibody tests. Standard antifungal medication (voriconazole) taken by mouth for four months completely resolved the infection, highlighting the need to consider rare fungi in patients receiving advanced cancer immunotherapies.

Read More »
Scroll to Top